Send to

Choose Destination
J Surg Oncol. 2010 Feb 1;101(2):145-8. doi: 10.1002/jso.21445.

Prostate stem cell antigen mRNA in peripheral blood as a potential predictor of biochemical recurrence in high-risk prostate cancer.

Author information

Urologic Oncology Clinic, Center for Specific Organs Cancer, National Cancer Center, Goyang, Republic of Korea.



To determine whether the presence of prostate stem cell antigen (PSCA) mRNA in peripheral blood can predict biochemical recurrence (BCR) after radical prostatectomy in patients with high-risk prostate cancer.


High-risk disease was defined based on the presence of any one of the following three risk factors: prostate-specific antigen (PSA) > or = 20 ng/ml, a biopsy Gleason score (GS) > or = 8, or clinical stage > or = T2c. Nested reverse transcriptase-polymerase chain reaction (RT-PCR) was employed to detect PSCA mRNA-bearing cells in peripheral blood. The relationship between PSCA detection and BCR after surgery was evaluated.


Of the 250 patients, 103 (36.8%) with high-risk disease were included in the analysis. PSCA-mRNA was detected in 17 (16.5%) of these patients. Patients with high GS (> or = 7) tended to be PSCA-mRNA positive status (P = 0.045). Over a median 23 months of follow-up (range 3-47 months), BCR developed in 27 patients (26.2%). Cox regression hazards model analysis revealed that a RT-PCR PSCA positivity (HR, 4.549; 95%CI, 1.685-12.279; P = 0.003) independently increased the risk of BCR.


The presence of PSCA mRNA in peripheral blood is a significant predictor of BCR after radical prostatectomy in high-risk prostate cancer.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center